Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIRUM PHARMACEUTICALS, INC.

(MIRM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Mirum Pharmaceuticals : Partners With Takeda Over Developing, Commercializing Liver Disease Drug Candidate in Japan

09/21/2021 | 11:11am EDT


© MT Newswires 2021
All news about MIRUM PHARMACEUTICALS, INC.
09/30MIRUM PHARMACEUTICALS : HC Wainwright Raises Price Target for Mirum Pharmaceuticals to $64..
MT
09/30MIRUM PHARMACEUTICALS : Baird Adjusts Mirum Pharmaceuticals PT to $34 From $30, Maintains ..
MT
09/30MIRUM PHARMACEUTICALS : SVB Leerink Adjusts Price Target on Mirum Pharmaceuticals to $41 F..
MT
09/30MIRUM PHARMACEUTICALS : Raymond James Adjusts Mirum Pharmaceuticals PT to $69 from $51, Ma..
MT
09/29MIRUM PHARMACEUTICALS : U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only App..
PU
09/29MIRUM PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Other Events, Fi..
AQ
09/29MIRUM PHARMACEUTICALS : Gets FDA's OK for Livmarli Oral Solution to Treat Chronic Itch in ..
MT
09/29MIRUM PHARMACEUTICALS : oral drug becomes first U.S. approved Alagille syndrome therapy
RE
09/29MIRUM PHARMACEUTICALS : FDA approves Mirum Pharma's drug for itching associated with rare ..
RE
09/29MIRUM PHARMACEUTICALS : U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only App..
BU
More news
Analyst Recommendations on MIRUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 35,1 M - -
Net income 2021 -167 M - -
Net cash 2021 259 M - -
P/E ratio 2021 -2,98x
Yield 2021 -
Capitalization 501 M 501 M -
EV / Sales 2021 6,91x
EV / Sales 2022 4,56x
Nbr of Employees 120
Free-Float 90,5%
Chart MIRUM PHARMACEUTICALS, INC.
Duration : Period :
Mirum Pharmaceuticals, Inc. Technical Analysis Chart | MIRM | US6047491013 | MarketScreener
Technical analysis trends MIRUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 16,53 $
Average target price 54,57 $
Spread / Average Target 230%
EPS Revisions
Managers and Directors
Christopher Peetz President, Chief Executive Officer & Director
Ian Clements Chief Financial Officer
Michael G. Grey Chairman
Pamela Vig Chief Scientific Officer
Edwin J. Tucker Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MIRUM PHARMACEUTICALS, INC.-5.33%501
MODERNA, INC.220.51%135 157
LONZA GROUP AG27.29%58 232
IQVIA HOLDINGS INC.38.67%47 608
SEAGEN INC.-1.81%31 287
CELLTRION, INC.-39.69%24 952